SAN DIEGO, Jan. 12 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will release its fourth quarter and full year 2005 financial results on Wednesday, February 15, 2006 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call at 4:30 p.m. ET hosted by Henry L. Nordhoff, chairman, president and chief executive officer, and Herm Rosenman, vice president, finance and chief financial officer.
The conference call will be webcast live and may be accessed on the investment information section of the Company's web site at http://www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 888-566-0043 (U.S.) or 402-998-1629 (international).
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. The Company also developed and manufactures the only FDA-approved blood screening assay for the simultaneous detection of HIV-1 and HCV, which is marketed by Chiron Corporation. In addition, Gen-Probe's TIGRIS instrument is the only fully automated, high-throughput NAT system for diagnostics and blood screening. Gen-Probe has more than 20 years of NAT expertise, and its products are used daily in clinical laboratories and blood collection centers worldwide. The Company received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 900 people. For more information, go to http://www.gen-probe.com.
Gen-Probe IncorporatedCONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,+1-858-410-8904, or paulai@gen-probe.com
Web site: http://www.gen-probe.com/
